|
|
 Previous Article | Table of Contents | Next Article 
Interleukin-6 (B-cell stimulatory factor 2)-dependent growth of a Lennert's
lymphoma-derived T-cell line (KT-3)
S Shimizu, T Hirano, R Yoshioka, S Sugai, T Matsuda, T Taga, T Kishimoto and S Konda
Kanazawa Medical University, Department of Internal Medicine, Ishikawa,
Japan.
A T lymphoma cell line (KT-3) established from a patient with Lennert's
lymphoma showed macrophage-dependent growth. Macrophage-derived factors
were able to replace the macrophage functions. Experiments using a variety
of cytokines demonstrated that KT-3 proliferated in response to recombinant
interleukin-2 (rIL-2), rIL-4, or rIL-6 but did not proliferate in response
to rIL-1 alpha, rIL-1 beta, rIL-3, recombinant granulocyte
colony-stimulating factor (rG-CSF), rGM-CSF, recombinant interferon-alpha
(rIFN-alpha), rIFN-gamma, recombinant tumor necrosis factor (rTNF-alpha),
or native IFN-beta. Polyclonal rabbit anti-IL-6 antibody almost completely
neutralized the activities of macrophage- derived factors or IL-6 but not
IL-2 or IL-4. Scatchard plot analysis demonstrated that KT-3 cells indeed
express IL-6 receptors. The results indicate that the macrophage-derived
factor that supports the growth of KT-3 is IL-6 and suggest that
macrophage-derived IL-6 may play an important role in the histopathogenesis
of Lennert's lymphoma.
Volume 72,
Issue 5,
pp. 1826-1828,
11/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Yoshio-Hoshino, Y. Adachi, C. Aoki, A. Pereboev, D. T. Curiel, and N. Nishimoto
Establishment of a New Interleukin-6 (IL-6) Receptor Inhibitor Applicable to the Gene Therapy for IL-6-Dependent Tumor
Cancer Res.,
February 1, 2007;
67(3):
871 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Conze, L. Weiss, P. S. Regen, A. Bhushan, D. Weaver, P. Johnson, and M. Rincon
Autocrine Production of Interleukin 6 Causes Multidrug Resistance in Breast Cancer Cells
Cancer Res.,
December 1, 2001;
61(24):
8851 - 8858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fayad, M. J. Keating, J. M. Reuben, S. O'Brien, B.-N. Lee, S. Lerner, and R. Kurzrock
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome
Blood,
January 1, 2001;
97(1):
256 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Daino, I. Matsumura, K. Takada, J. Odajima, H. Tanaka, S. Ueda, H. Shibayama, H. Ikeda, M. Hibi, T. Machii, et al.
Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells
Blood,
April 15, 2000;
95(8):
2577 - 2585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kiuchi, K. Nakajima, M. Ichiba, T. Fukada, M. Narimatsu, K. Mizuno, M. Hibi, and T. Hirano
STAT3 Is Required for the gp130-mediated Full Activation of the c-myc Gene
J. Exp. Med.,
January 4, 1999;
189(1):
63 - 73.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. N. Tsitsikov, D. A. Wright, and R. S. Geha
CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2
PNAS,
February 18, 1997;
94(4):
1390 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Taga, M. Hibi, Y. Hirata, H. Yawata, S. Natsuka, K. Yasukawa, T. Totsuka, K. Yamasaki, T. Hirano, and T. Kishimoto
Interleukin-6 Receptor and a Unique Mechanism of Its Signal Transduction
Cold Spring Harb Symp Quant Biol,
January 1, 1989;
54(0):
713 - 722.
[Abstract]
[PDF]
|
|
|
|
|
